AIM3 Antibody

What is AIMP3 and why is it important in genomic research?

AIMP3 (also known as p18 or EEF1E1) functions as a component of the multi-aminoacyl-tRNA synthetase complex and plays critical roles in diverse cellular processes. It has been identified as a tumor suppressor and positive modulator of the ATM response to DNA damage . Research indicates that AIMP3 is essential for maintaining genome integrity, particularly through its involvement in DNA repair processes . The protein's significance stems from its role in embryonic development—AIMP3 deficiency causes early embryonic lethality in mice—suggesting its fundamental importance in essential biological processes .

What experimental models are available for studying AIMP3 function?

Several experimental models have been developed to study AIMP3 function:

• Conditional knockout mouse models: AIMP3^f/f;Cre^ERT2 mice allow for temporal systemic deletion of AIMP3 using tamoxifen induction .

• Mouse embryonic stem cells (mESCs): Derived from blastocysts of AIMP3^f/f;Cre^ mice, these provide insights into AIMP3's role in stemness maintenance .

• AIMP3-depleted cell lines: Created through knockdown techniques to study cellular consequences of AIMP3 reduction .

• MEFs (Mouse Embryonic Fibroblasts): Isolated from conditional knockout mice to examine DNA repair mechanisms .

These models offer complementary approaches to investigating AIMP3's functions in different cellular contexts and developmental stages.

How does AIMP3 contribute to DNA damage response mechanisms?

AIMP3 plays multiple roles in DNA damage response:

• DNA double-strand break repair: AIMP3 is critical for efficient repair of double-strand breaks, particularly through the homologous recombination (HR) pathway .

• DSB recognition and signaling: While AIMP3 depletion doesn't significantly affect initial recognition of DSBs or activation of ATM and ATR pathways, it substantially impairs downstream repair events .

• Repair kinetics: AIMP3-depleted cells show delayed clearance of γH2AX foci (a marker of DNA damage), indicating slower repair processes .

• HR repair efficiency: Reporter assays show that AIMP3 knockdown reduces HR efficiency to approximately 60% compared to controls, while NHEJ (non-homologous end joining) appears less affected .

The protein's involvement in these processes explains why its absence leads to significant genome instability and hypersensitivity to radiation.

What are the optimal protocols for detecting AIMP3 expression in different tissue types?

For effective detection of AIMP3 across various tissue types, researchers should consider multiple complementary approaches:

When selecting antibodies, consider using rabbit-derived polyclonal antibodies with demonstrated cross-reactivity to the species of interest. Commercial AIMP3 antibodies typically target epitopes within amino acids 101-174 of the 174-amino acid human AIMP3 protein, offering good cross-species reactivity .

For tissue preparation, note that AIMP3 has dual subcellular localization (cytoplasm and nucleus), and translocation between compartments occurs during DNA damage response, requiring preservation of both compartments during sample preparation .

How can researchers effectively measure AIMP3's role in DNA repair mechanisms?

To evaluate AIMP3's function in DNA repair, several complementary assays can be implemented:

• γH2AX foci analysis:

  • Use immunofluorescence to quantify foci formation after DNA damage induction (e.g., irradiation)

  • Track foci clearance over time (2h, 4h, 6h post-irradiation) to measure repair kinetics

  • AIMP3-depleted cells typically show comparable initial foci formation but significantly delayed clearance

• Comet assay:

  • Implement alkaline comet assay to detect DNA breaks

  • Measure olive tail moment to quantify DNA damage

  • AIMP3-depleted cells show increased baseline tail moment even without external damage stimulus

• HR and NHEJ reporter assays:

  • Transfect cells with linearized DR-GFP (for HR) and EJ5-GFP (for NHEJ) constructs

  • Measure GFP expression as indicator of successful repair

  • Compare repair efficiency between AIMP3-normal and AIMP3-depleted conditions

• RPA and Rad51 foci formation:

  • Examine formation of RPA and subsequent Rad51 foci as markers of HR pathway activation

  • AIMP3 depletion typically reduces formation of these foci, indicating impaired HR pathway initiation

These assays together provide comprehensive assessment of AIMP3's role in maintaining genomic integrity through DNA repair mechanisms.

What considerations are important when developing experimental timelines for AIMP3 knockout studies?

When designing temporal experiments with AIMP3 knockout models, several critical factors must be addressed:

• Induction method timing:

  • For tamoxifen-inducible Cre systems, peak AIMP3 deletion occurs 3-5 days post-induction

  • Plan timepoints accordingly to capture early phenotypic changes before potential lethality

• Developmental stage considerations:

  • Complete embryonic AIMP3 knockout results in early lethality

  • For developmental studies, conditional knockouts in specific tissues may be more informative

• Phenotype progression timeline:

  • Acute radiation syndrome-like phenotypes develop rapidly after systemic deletion

  • Monitor for scleroderma, haematopoietic hypotrophy, and intestinal failure within 7-14 days

• Cell-specific recovery dynamics:

  • Different cell populations show variable recovery capacity after AIMP3 depletion

  • Highly proliferative tissues (intestinal epithelium, bone marrow) show fastest phenotype manifestation

• Irradiation challenge protocols:

  • When combining AIMP3 knockout with radiation challenge, sub-lethal doses should be administered 3-5 days after tamoxifen induction

  • Survival assessment requires 30+ days of monitoring

Researchers should conduct preliminary pilot studies to determine optimal timepoints specific to their experimental system and research questions.

How can researchers distinguish between direct and indirect effects of AIMP3 depletion?

Differentiating direct consequences of AIMP3 loss from secondary effects requires systematic experimental approaches:

• Rescue experiments:

  • Reintroduce wild-type AIMP3 to knockout/knockdown systems

  • If phenotypes reverse, they likely represent direct AIMP3 effects

  • Design domain-specific mutants to identify which AIMP3 functions are responsible for specific phenotypes

• Temporal analysis:

  • Document sequential appearance of phenotypes after AIMP3 depletion

  • Earlier effects (γH2AX accumulation, impaired HR) are likely direct, while later effects (differentiation, apoptosis) may be consequential

• Pathway inhibition studies:

  • Combine AIMP3 depletion with inhibition of downstream pathways

  • For example, p53 knockdown rescues loss of stemness in AIMP3-depleted mESCs, suggesting stemness loss is indirect via p53 activation

• Separation of functions:

  • AIMP3 has both tRNA synthetase complex-related and DNA repair functions

  • Use domain-specific mutations to determine which functions contribute to observed phenotypes

• Gene expression profiling:

  • Compare transcriptional changes at early vs. late timepoints after AIMP3 depletion

  • Early transcriptional changes likely represent direct AIMP3 functions

This systematic approach helps establish causality rather than mere correlation in phenotypic analyses.

What are the key considerations when comparing AIMP3 antibody results across different detection methods?

When integrating AIMP3 data obtained through different detection methodologies, researchers should consider:

• Epitope accessibility variations:

  • Different antibodies target distinct AIMP3 regions (common epitope range: aa 101-174/174)

  • Protein conformation, complex formation, or post-translational modifications may affect epitope accessibility

  • Some detection methods may favor particular conformational states

• Sensitivity thresholds:

  • Western blotting typically has lower sensitivity than immunofluorescence or ELISA

  • Quantify detection limits for each method when comparing low AIMP3 expression samples

• Subcellular fractionation effects:

  • AIMP3 shuttles between cytoplasm and nucleus under different conditions

  • Whole-cell lysates may obscure compartment-specific changes

  • Consider specific extraction protocols for nuclear vs. cytoplasmic fractions

• Cross-reactivity profiles:

  • Antibodies may show different cross-reactivity with AIMP3 homologs across species

  • Verify species specificity when comparing data from human, mouse, or other models

• Data normalization approaches:

  • Establish consistent normalization strategies across techniques

  • For western blots, normalization to housekeeping proteins

  • For immunofluorescence, consider cell size and morphology variations

Maintaining detailed documentation of these variables facilitates more accurate cross-method data integration.

How do research findings on AIMP3 in embryonic stem cells translate to other cell types?

Translating AIMP3 research findings from embryonic stem cells to other cellular contexts requires careful consideration of several biological variables:

• Cell-specific DNA repair pathway utilization:

  • Embryonic stem cells predominantly rely on homologous recombination (HR) for DNA repair

  • Somatic cells utilize non-homologous end joining (NHEJ) more frequently

  • AIMP3's impact may vary based on preferred repair pathway

• Proliferation rate differences:

  • mESCs have exceptionally rapid cell cycles

  • AIMP3's role in genome stability may be more pronounced in rapidly dividing cells

  • Effects in slow-cycling cells may be less acute but accumulate over time

• p53 pathway variations:

  • In mESCs, AIMP3 depletion activates p53, leading to stemness loss

  • p53 response differs substantially across cell types

  • Verify p53 pathway activation in each specific cell type

• Contextual protein interactions:

  • AIMP3 participates in multi-protein complexes that vary across cell types

  • Interaction partners may modulate AIMP3 function in tissue-specific ways

• Differential expression levels:

  • AIMP3 expression is particularly high in embryonic tissues

  • Lower baseline expression in some differentiated cells may alter the impact of partial depletion

Researchers should validate key mechanisms in multiple cell types rather than assuming universal applicability of mESC findings.

What are common pitfalls in AIMP3 antibody experiments and how can they be addressed?

Researchers frequently encounter several challenges when working with AIMP3 antibodies that can be systematically addressed:

• Inconsistent detection issues:

  • Problem: Variable AIMP3 signal across experiments

  • Solution: Optimize antibody concentration (start with 1:300 for WB, 1:200 for IHC-P)

  • Validation: Include positive control samples with known AIMP3 expression

• High background in immunostaining:

  • Problem: Non-specific binding obscuring AIMP3-specific signal

  • Solution: Increase blocking time (minimum 1 hour), use 1-5% BSA in TBS buffer

  • Validation: Include secondary-only controls to identify antibody-independent background

• Nuclear vs. cytoplasmic localization discrepancies:

  • Problem: Inconsistent subcellular localization patterns

  • Solution: Document cell treatment conditions; AIMP3 shuttles between compartments during stress response

  • Validation: Use cell fractionation followed by western blotting to confirm localization

• Cross-reactivity concerns:

  • Problem: Signal in presumed negative control samples

  • Solution: Validate antibody specificity using AIMP3 knockout/knockdown samples

  • Validation: Peptide competition assays to confirm epitope specificity

• Storage-related sensitivity loss:

  • Problem: Decreased sensitivity after antibody storage

  • Solution: Store at -20°C with 50% glycerol to prevent freeze-thaw damage

  • Validation: Aliquot antibodies to minimize freeze-thaw cycles

Maintaining detailed laboratory records of these variables facilitates troubleshooting and improves experimental reproducibility.

How can researchers validate the specificity of their AIMP3 antibody?

Comprehensive validation of AIMP3 antibody specificity requires a multi-faceted approach:

• Genetic validation:

  • Test antibody in AIMP3 knockout/knockdown models

  • Expect significant signal reduction proportional to depletion efficiency

  • Use inducible knockout systems to demonstrate temporal correlation between depletion and signal reduction

• Peptide competition assays:

  • Pre-incubate antibody with excess synthetic AIMP3 peptide (the immunogen)

  • Specificity is confirmed if this pre-treatment abolishes or significantly reduces signal

  • Use non-relevant peptides as negative controls

• Multiple antibody comparison:

  • Test antibodies targeting different AIMP3 epitopes

  • Consistent localization and expression patterns support specificity

  • Discrepancies may indicate off-target binding or context-dependent epitope masking

• Recombinant protein detection:

  • Test antibody against purified recombinant AIMP3

  • Confirm detection at expected molecular weight (~18 kDa for AIMP3/p18)

  • Include size-matched non-AIMP3 proteins as negative controls

• Immunoprecipitation validation:

  • Perform IP with anti-AIMP3 antibody followed by mass spectrometry

  • Confirm AIMP3 as predominant precipitated protein

  • Identify potential cross-reactive proteins for awareness in data interpretation

Documentation of these validation steps should accompany research publications to establish confidence in antibody specificity.

How can AIMP3 antibodies be utilized to study radiation sensitivity mechanisms?

AIMP3 antibodies provide valuable tools for investigating radiation sensitivity mechanisms through several experimental approaches:

• Radiation response biomarker studies:

  • Use anti-AIMP3 antibodies to track AIMP3 subcellular translocation after radiation exposure

  • Monitor correlation between AIMP3 nuclear translocation and radiation dose

  • Combine with γH2AX staining to correlate AIMP3 activity with DNA damage resolution

• Predictive biomarker development:

  • Characterize AIMP3 expression/localization patterns in radiation-resistant vs. sensitive tissues

  • Develop standardized IHC-based scoring systems for AIMP3 status

  • Correlate with clinical radiation response data

• Mechanistic pathway analysis:

  • Combine AIMP3 immunoprecipitation with co-IP for DNA repair partners

  • Use proximity ligation assays to detect radiation-induced AIMP3 interactions

  • Compare interaction networks in radiation-sensitive vs. resistant cellular contexts

• Therapeutic target identification:

  • Screen for compounds that enhance AIMP3 stability or nuclear translocation

  • Evaluate potential radiation sensitization in AIMP3-deficient tumors

  • Use AIMP3 antibodies to monitor target engagement

• In vivo radiosensitivity models:

  • Track AIMP3 levels in conditional knockout mice after sub-lethal irradiation

  • Correlate tissue-specific AIMP3 levels with radiation syndrome manifestations

  • Develop antibody-based tissue imaging for radiation damage assessment

These approaches leverage AIMP3 antibodies to advance radiation biology research and potentially improve radiotherapy safety and efficacy.

What are the emerging applications of AIMP3 antibodies in cancer research?

AIMP3 antibodies are increasingly valuable in cancer research applications based on AIMP3's established tumor suppressor functions:

• Prognostic biomarker development:

  • Analyze AIMP3 expression patterns across tumor types and stages

  • Correlate expression with patient outcomes and treatment responses

  • Develop standardized IHC scoring systems for clinical application

• DNA damage response profiling:

  • Characterize AIMP3-dependent repair pathway functionality in tumors

  • Identify tumors with defective AIMP3-mediated repair as candidates for synthetic lethal approaches

  • Combine with other DNA repair markers (BRCA1/2, ATM) for comprehensive profiling

• Therapeutic response prediction:

  • Monitor AIMP3 status before and during genotoxic chemotherapy

  • Correlate changes in AIMP3 localization with treatment effectiveness

  • Develop dynamic biomarkers of emerging resistance

• Genome stability assessment:

  • Use AIMP3 antibodies to assess repair capacity in circulating tumor cells

  • Correlate with genomic instability signatures from tumor sequencing

  • Monitor therapy-induced changes in repair capacity

• Therapeutic target validation:

  • Identify tumors with AIMP3 pathway dependencies

  • Develop strategies to enhance AIMP3 function in AIMP3-deficient tumors

  • Use antibodies to monitor target engagement of AIMP3-modulating therapeutics

These applications highlight the translational potential of basic AIMP3 research in clinical oncology.

What emerging technologies are likely to advance AIMP3 antibody research?

Several cutting-edge technologies are poised to transform AIMP3 antibody applications in research:

• Single-cell antibody-based technologies:

  • Single-cell Western blotting to analyze AIMP3 expression heterogeneity

  • Mass cytometry (CyTOF) incorporating AIMP3 antibodies for high-dimensional phenotyping

  • Microfluidic approaches for analyzing AIMP3 dynamics in rare cell populations

• Spatially-resolved antibody methods:

  • Multiplexed ion beam imaging (MIBI) to map AIMP3 alongside dozens of other proteins

  • Spatial transcriptomics combined with AIMP3 protein detection

  • 3D tissue imaging to understand AIMP3 distribution in intact organs

• Proximity-based interaction mapping:

  • BioID or APEX2 proximity labeling fused to AIMP3 to map interaction partners

  • Proximity ligation assays to detect AIMP3 interactions in situ

  • FRET-based biosensors to monitor AIMP3 conformational changes in living cells

• Antibody engineering advances:

  • Nanobodies against AIMP3 for improved access to conformational epitopes

  • Bispecific antibodies targeting AIMP3 and interacting proteins

  • Intrabodies for tracking AIMP3 in living cells without overexpression artifacts

• In vivo applications:

  • Antibody-based in vivo imaging of AIMP3 status

  • Targeted delivery of therapeutics to AIMP3-deficient tissues

  • CRISPR-based screens combined with AIMP3 antibody readouts

These technological advances will likely accelerate discovery in AIMP3 biology and potentially lead to novel diagnostic and therapeutic applications.

How can researchers integrate AIMP3 antibody data with other omics approaches?

Effective integration of AIMP3 antibody data with multi-omics datasets requires systematic analytical strategies:

• Genomic-proteomic correlation:

  • Connect AIMP3 gene mutations/variants with protein expression patterns

  • Analyze effects of copy number alterations on AIMP3 protein levels

  • Investigate epigenetic regulation mechanisms explaining discordant mRNA-protein levels

• Transcriptome-proteome integration:

  • Compare AIMP3 mRNA expression with protein levels across tissues and conditions

  • Identify post-transcriptional regulatory mechanisms

  • Use antibodies to validate findings from transcript-based studies

• Protein interaction network mapping:

  • Combine AIMP3 immunoprecipitation with mass spectrometry to identify interactors

  • Correlate interaction patterns with functional outcomes

  • Validate computationally predicted interactions using co-IP with AIMP3 antibodies

• Functional genomics validation:

  • Use AIMP3 antibodies to validate findings from genetic screens

  • Measure AIMP3 protein levels/localization after perturbation of regulatory genes

  • Develop scalable AIMP3 antibody-based readouts for high-throughput screens

• Multi-modal data visualization platforms:

  • Develop interactive tools to visualize AIMP3 protein data alongside other omics datasets

  • Implement machine learning approaches to identify patterns across data types

  • Create pathway-level visualizations incorporating AIMP3 status

This integrated approach enables researchers to develop more comprehensive models of AIMP3 function in complex biological systems.